Advanced searches left 3/3

Levofloxacin - DOAJ

Summarized by Plex Scholar
Last Updated: 08 June 2022

* If you want to update the article please login/register

Two-day seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial

"Introduction: The duration of antibiotic therapy in acute exacerbation of COPD is the most commonly based on expert opinion. " Patients with AECOPD under AECOPD under AECOPD's 2-day versus 7-day treatment with levofloxacin in patients with AECOPD under AECOPD's randomized clinical trial. Patients with AECOPD were randomly assigned to receive levofloxacin for 2 days and 5 days placebo or levofloxacin for 7 days. For five days, all patients received a single dose of intravenous prednisone daily. According to the EFI, the two-year re-exacerbation rate in a 2-day group was 38. 8% versus 29 percent in a 7-day group; the EFI was 121 days versus 110 days in 2-day and 7-day therapy groups, respectively; According to the 2 groups, 5. 2% versus 7. 1% in the 2-day group and 7-day group, respectively, and the 7-day group did not differ significantly between the two groups, with 5. 2% versus 7. 1% in the 2-day group and the 7-day group, respectively; "".

Source link: https://doi.org/10.1177/17534666221099729


Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey

"INTRODUCTION: Antibiotic resistance is the most significant factor that has a direct influence on the effectiveness of new therapeutic regimens against Helicobacter pylori. " Among H. pylori strains isolated from Turkish patients with dyspepsia, this research was conducted to determine the incidence of resistance to efficacy clarithromycin, amoxicillin, tetracycline, levofloxacin, and metronidazole. METHODS: H. pylori was cultured from corpus and antrum biopsies that were obtained from patients with dyspeptic signs, and the antimicrobial susceptibility of H. pylori was determined using the E-test, according to the EUCAST breakpoints. RESULTS: A total of 98 H. pylori strains had been isolated, the majority of which were amoxicillin-resistant and tetracycline-resistant, and none of them were amoxicillin-resistant. In addition, the levofloxacin MIC values in our H. pylori strains increased to 32 mg/L. We conclude that the treatment failure after clarithromycin- or levofloxacin-based triple therapy is not surprising, and that metronidazole is not a good agent for the eradication of H. pylori infection in Turkey.

Source link: https://doi.org/10.1590/0037-8682-0027-2015


Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients

"Abstract" is the product of a student's "Abstract" has been used for the past 25 years, but there are no pharmacokinetic studies to guide levofloxacin dosing in adult patients. This research was designed to produce a pharmacokinetic model of levofloxacin for adult hospitalized patients and establish dosing regimens that meet a pharmacokinetic/pharmacodynamic target of maximum efficiency. Our simulation revealed that an area under free concentration curve to MIC u2265 1 mg/L was barely reached for pathogens with MIC >u2265 1 mg/L. Patients with higher eGFR were observed with Pseudomonas aeruginosa and Streptococcus pneumoniae. Low FTA against Pseudomonas aeruginosa and Streptococcus pneumoniae were seen in patients with elevated eGFR.

Source link: https://doi.org/10.1038/s41598-022-12627-1


Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation

The absence of any apparent chemical interaction between the drug and the polymer used for the manufacture of microspheres was shown by quantitative testing calorimetry, Fourier transform infrared spectroscopy, and X-ray diffraction results. Comparing to plain LVX, In vivo results showed that LVX-loaded microspheres had superior lung accumulation, as shown by a two-fold rise in the area under the curve AUC 0-1324h. In addition, LVX-loaded microspheres prolonged drug residence time in the lung and maintained a relatively high drug content for a longer time, contributing to a reduced leakage in the systemic circulation. In conclusion, inhalable LVX-loaded microspheres may be a safe delivery device for targeting pulmonary tuberculosis by increasing the therapeutic efficacy of LVX while minimising systemic off-target side effects. ".

Source link: https://doi.org/10.3390/ph15050560

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions